English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Pulmonary arterial hypertension (PAH) is a multi-factorial, progressive disease with substantial mortality and morbidity. Despite recent improvements in treatment, mortality associated with PAH remains high, with a two-year survival rate after diagnosis of approximately 85% (Thenappan et al., 2007). Although advances in the understanding of disease development and treatment have been achieved, the pathogenesis of PAH is still not clearly understood (Humbert et al., 2004). Therapeutic options remain limited despite the introduction of prostacyclin analogues, endothelin receptor antagonists and phosphodiesterase 5 inhibitors within the last 15 years. Moreover, these interventions predominantly address the endothelial and vascular dysfunction associated with the condition, and thus merely delay the progression of the disease rather than offer a cure (McLaughlin et al., 2009a, McLaughlin et al., 2009b).

&#969;3 and &#969;6 CYP450 Eicosanoid Derivatives: Key Lipid Mediators in the Regulation of Pulmonary Hypertension

ω3 and ω6 CYP450 Eicosanoid Derivatives: Key Lipid Mediators in the Regulation of Pulmonary Hypertension